TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| FDA to Look at Walgreen Genetic-Test Product The FDA plans to take a look at a new genetic test, made by Pathway Genomics, that Walgreen plans to start selling at its stores this month. online.wsj.com |
Study: Cholesterol Screens Miss Kids A new study suggests that guidelines for screening children for high cholesterol fail to capture many youngsters with elevated levels who might benefit from healthier diet and exercise habits or treatment with cholesterol-lowering medication. online.wsj.com |
Jazz: Your FDA Panel Primer Rockford Coscia submits:Jazz Pharmaceuticals (JAZZ) is a small biotech firm specializing in treatments for neurology and psychiatry patients. Jazz has two products currently being marketed in the U.S.: Xyrem for the treatment of narcolepsy, and Luvox CR for the treatment of social anxiety disorder and obsessive compulsive disorder. Currently, a new drug application is under review for Jazz's fibromyalgia therapy currently referred to as JZP-6. As part of the evaluation process, the FDA has scheduled a panel, in which it consults experts for potential concerns, for August 20. FDA panels usually cause significant price swings in the stock in the company under evaluation -- so much so that trading is halted for the entire day that the panel takes place. Due to the potentially huge price swing in Jazz's stock, I wanted to address what I thought was especially important for investors (and speculators!) to know heading into this event.Complete Story » seekingalpha.com |
Egg Company Owner Apologizes As Lawmakers Examine Outbreak Iowa chicken farmer Austin DeCoster apologized to victims of the salmonella outbreak that led to the summer's nationwide egg recall and promised to take steps to prevent further contamination. online.wsj.com |
The Pros of Protalix Shlomi Cohen submits: One of the Israeli companies whose shares I hold in my portfolio tracked by "Globes", and that has risen significantly since the beginning of the July, is Protalix Biotherapeutics Inc. (AMEX:PLX). The share rose more than 55% in that period, without major news, and before gaining long-awaited US Food and Drug Administration (FDA) approval for its Gaucher's disease treatment.Many undoubtedly remember how almost exactly a year ago, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) chairman Dr. Phillip Frost sold shares at what looked to be a fire sale, at prices around $6 a share. We asked then if Frost knew something we didn't.Complete Story » seekingalpha.com |